Serum prostate-specific antigen as a predictor of prostate volume in Sudanese patients with benign prostatic hyperplasia

  • Authors

    • Awad Alawad University of Medical Sciences and Technology
    • Faisal Younis University of Medical Sciences and Technology
    • Abdalla Mahgoub Eltoum University of Medical Sciences and Technology
    • Sana Azmi Abdelgani
    2014-05-20
    https://doi.org/10.14419/ijm.v2i1.2494

  • Background: Benign prostatic hyperplasia (BPH) is now recognized as one of the principal medical problems facing the male population in Sudan.

    Objective: The aim of this study is to assess the ability of serum prostate-specific antigen (PSA) to predict prostate volume (PV) in patients with benign prostatic hyperplasia (BPH).

    Materials and Methods: This is retrospective observational case-detection hospital based study. Eighty medical records of patients with an enlarged prostate attending the urology clinic at University Teaching Hospital were enrolled.  This research was conducted in University Charity Teaching Hospital, Khartoum, Sudan.

    Results: Enrolled patients had a median age of 63.5 years (51 to 94), a mean PSA of 2.94 ng/ mL and a mean PV of 46.96 mL, respectively. There is linear relationship between PSA levels and prostate size. Those with a prostate size of > 40 ml were found to be more likely to have high PSA mean level. PSA mean values were found to be associated with age (P <0.006).

    Conclusion: Serum prostate specific antigen (PSA) is significantly correlated with prostate volume in Sudanese men. PSA may be a useful tool in making therapeutic decisions and follow-up management in BPH patients.

     

    Keywords: Serum Prostate Specific Antigen; Prostate Volume; Benign Prostatic Hyperplasia.

  • References

    1. Bohnen AM, Groeneveld FP & Bosch JL (2007): Serum prostate-specific antigen as a predictor of prostate volume in the community: the Krimpen study. Eur Urol 51, 1645-1652; discussion 1652-1643.
    2. Canto EI, Singh H, Shariat SF, Lamb DJ, Mikolajczyk SD, Linton HJ, Rittenhouse HG, Kadmon D, Miles BJ & Slawin KM (2004): Serum BPSA outperforms both total PSA and free PSA as a predictor of prostatic enlargement in men without prostate cancer. Urology 63, 905-910; discussion 910-901.
    3. Choi H, Park JY, Shim JS, Kim JH & Bae JH (2013): Free prostate-specific antigen provides more precise data on benign prostate volume than total prostate-specific antigen in korean population. Int Neurourol J 17, 73-77.
    4. Chung BH, Hong SJ, Cho JS & Seong DH (2006): Relationship between serum prostate-specific antigen and prostate volume in Korean men with benign prostatic hyperplasia: a multicentre study. BJU Int 97, 742-746.
    5. Furuya Y, Ohta S, Sato N, Kotake T & Masai M (2001): Prostate-specific antigen, prostate volume and transition zone volume in Japanese patients with histologically proven benign prostatic hyperplasia. Int Urol Nephrol 33, 645-648.
    6. Jara Rascon J, Subira Rios D, Lledo Garcia E, Martinez Salamanca JI, Moncada Iribarren I, Cabello Benavente R & Hernandez Fernandez C (2005): [Parameters with possible influence in PSA adjusted for transition zone volume]. Actas Urol Esp 29, 473-480.
    7. Kalish J, Cooner WH & Graham SD, Jr. (1994): Serum PSA adjusted for volume of transition zone (PSAT) is more accurate than PSA adjusted for total gland volume (PSAD) in detecting adenocarcinoma of the prostate. Urology 43, 601-606.
    8. Kravchick S, Bunkin I, Peled R, Yulish E, Ben-Dor D, Kravchenko Y & Cytron S (2007): Patients with elevated serum PSA and indwelling catheter after acute urinary retention: prospective study of 63 patients with 7-year follow-up. J Endourol 21, 1203-1206.
    9. Kwon H, Kang HC & Lee JH (2013): Relationship between predictors of the risk of clinical progression of benign prostatic hyperplasia and metabolic syndrome in men with moderate to severe lower urinary tract symptoms. Urology 81, 1325-1329.
    10. Lazzeri M, Haese A, Abrate A, de la Taille A, Redorta JP, McNicholas T, Lughezzani G, Lista G, Larcher A, Bini V, Cestari A, Buffi N, Graefen M, Bosset O, Le Corvoisier P, Breda A, de la Torre P, Fowler L, Roux J & Guazzoni G (2013): Clinical performance of serum prostate-specific antigen isoform [-2]proPSA (p2PSA) and its derivatives, %p2PSA and the prostate health index (PHI), in men with a family history of prostate cancer: results from a multicentre European study, the PROMEtheuS project. BJU Int 112, 313-321.
    11. Mochtar CA, Kiemeney LA, van Riemsdijk MM, Barnett GS, Laguna MP, Debruyne FM & de la Rosette JJ (2003): Prostate-specific antigen as an estimator of prostate volume in the management of patients with symptomatic benign prostatic hyperplasia. Eur Urol 44, 695-700.
    12. Park DS, Oh JJ, Hong JY, Hong YK, Choi DK, Gong IH, Hwang JH & Kwon SW (2013): Serum prostate-specific antigen as a predictor of prostate volume and lower urinary tract symptoms in a community-based cohort: a large-scale Korean screening study. Asian J Androl 15, 249-253.
    13. Roehrborn CG, McConnell J, Bonilla J, Rosenblatt S, Hudson PB, Malek GH, Schellhammer PF, Bruskewitz R, Matsumoto AM, Harrison LH, Fuselier HA, Walsh P, Roy J, Andriole G, Resnick M & Waldstreicher J (2000): Serum prostate specific antigen is a strong predictor of future prostate growth in men with benign prostatic hyperplasia. PROSCAR long-term efficacy and safety study. J Urol 163, 13-20.
    14. Shim HB, Lee JK, Jung TY & Ku JH (2007): Serum prostate-specific antigen as a predictor of prostate volume in Korean men with lower urinary tract symptoms. Prostate Cancer Prostatic Dis 10, 143-148.
    15. Stravodimos KG, Petrolekas A, Kapetanakis T, Vourekas S, Koritsiadis G, Adamakis I, Mitropoulos D & Constantinides C (2009): TRUS versus transabdominal ultrasound as a predictor of enucleated adenoma weight in patients with BPH: a tool for standard preoperative work-up? Int Urol Nephrol 41, 767-771.
    16. Tubaro A, Trucchi A & Miano L (2003): Investigation of benign prostatic hyperplasia. Curr Opin Urol 13, 17-22.

  • Downloads

  • How to Cite

    Alawad, A., Younis, F., Eltoum, A. M., & Abdelgani, S. A. (2014). Serum prostate-specific antigen as a predictor of prostate volume in Sudanese patients with benign prostatic hyperplasia. International Journal of Medicine, 2(1), 40-42. https://doi.org/10.14419/ijm.v2i1.2494